International Lung Cancer Congress

Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain

Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.

Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.

Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.

Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

Antibody-drug conjugates represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer and small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.